192 related articles for article (PubMed ID: 35532193)
1. Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study.
Ahn SH; Ahn SS; Park YW; Park CJ; Lee SK
Neuroradiol J; 2023 Feb; 36(1):49-58. PubMed ID: 35532193
[TBL] [Abstract][Full Text] [Related]
2. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
3. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
[TBL] [Abstract][Full Text] [Related]
4. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Hilario A; Hernandez-Lain A; Sepulveda JM; Lagares A; Perez-Nuñez A; Ramos A
Neurocirugia (Astur : Engl Ed); 2019; 30(1):11-18. PubMed ID: 30143443
[TBL] [Abstract][Full Text] [Related]
5. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
6. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
7. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
8. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
[TBL] [Abstract][Full Text] [Related]
9. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging.
Park YW; Ahn SS; Moon JH; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Neuroradiology; 2021 Nov; 63(11):1811-1822. PubMed ID: 33755766
[TBL] [Abstract][Full Text] [Related]
11. Simplified perfusion fraction from diffusion-weighted imaging in preoperative prediction of IDH1 mutation in WHO grade II-III gliomas: comparison with dynamic contrast-enhanced and intravoxel incoherent motion MRI.
Wang X; Cao M; Chen H; Ge J; Suo S; Zhou Y
Radiol Oncol; 2020 Jun; 54(3):301-310. PubMed ID: 32559177
[TBL] [Abstract][Full Text] [Related]
12. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
16. Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study.
Di N; Cheng W; Jiang X; Liu X; Zhou J; Xie Q; Chu Z; Chen H; Wang B
J Neuroradiol; 2019 May; 46(3):186-192. PubMed ID: 29752976
[TBL] [Abstract][Full Text] [Related]
17. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
18. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
[TBL] [Abstract][Full Text] [Related]
19. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
20. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.
Tatekawa H; Yao J; Oughourlian TC; Hagiwara A; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Salamon N; Ellingson BM
Clin Nucl Med; 2020 Dec; 45(12):e505-e511. PubMed ID: 33031233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
